Investing.com -- Alx Oncology Holdings (NASDAQ:ALXO) stock jumped 12% in premarket trading Monday after the clinical-stage biotechnology company reported impressive results from a Phase 2 trial of its cancer treatment evorpacept.
The study showed that combining evorpacept with standard-of-care rituximab and lenalidomide (R2) generated complete responses in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL). This compares favorably to the approximate 50% historical complete response rate for R2 alone.
The trial, presented at the American Society of Hematology Annual Meeting in Orlando, enrolled 24 previously untreated iNHL patients. All patients responded to the treatment, with 92% achieving complete responses and 8% partial responses. The one-year progression-free survival rate was 91%, while the one-year overall survival rate was 100%.
"We are excited to see the results of this Phase 2 study in frontline indolent non-Hodgkin lymphoma patients, where the addition of evorpacept added a meaningful benefit over the historical data for the standard-of-care regimen of rituximab and lenalidomide," said Jason Lettmann, Chief Executive Officer at ALX Oncology.
The company noted that the treatment combination was well-tolerated by patients. Researchers will continue to evaluate minimal residual disease eradication rates as longer-term follow-up data matures.
The study was conducted by Dr. Paolo Strati, Associate Professor of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, who pursued this frontline study after observing promising activity using the same combination in relapsed refractory settings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








